Neuroprotection in Parkinson’s disease: facts and hopes
Open Access
- 11 December 2019
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 127 (5) , 821-829
Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. Behind the symptoms there is a complex pathological mechanism which leads to a dopaminergic cell loss in the substantia nigra pars compacta. Despite the strong efforts, curative treatment has not been found yet. To prevent a further cell death, numerous molecules were tested in terms of neuroprotection in preclinical (in vitro, in vivo) and in clinical studies as well. The aim of this review article is to summarize our knowledge about the extensively tested neuroprotective agents (Search period: 1991–2019). We detail the underlying pathological mechanism and summarize the most important results of the completed animal and clinical trials. Although many positive results have been reported in the literature, there is still no evidence that any of them should be used in clinical practice (Cochrane analysis was performed). Therefore, further studies are needed to better understand the pathomechanism of PD and to find the optimal neuroprotective agent(s).Keywords
This publication has 111 references indexed in Scilit:
- The prion hypothesis in Parkinson's disease: Braak to the futureActa Neuropathologica Communications, 2013
- Pathogenesis of Parkinson's diseaseMovement Disorders, 2012
- Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjectsJournal of Clinical Pharmacy and Therapeutics, 2012
- Kynurenines in Parkinson’s disease: therapeutic perspectivesJournal of Neural Transmission, 2011
- The Promise of Neuroprotective Agents in Parkinson?s DiseaseFrontiers in Neurology, 2011
- Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degenerationExperimental Neurology, 2010
- Clinical progression in Parkinson disease and the neurobiology of axonsAnnals of Neurology, 2010
- Urate as a Predictor of the Rate of Clinical Decline in Parkinson DiseaseArchives of Neurology, 2009
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 1997